Search

Copyright of Transactions of the Chinese Society of Agricultural Engineering is the property of Chinese Society of Agricultural Engineering and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To observe the effects of Aidi injection combined with XELOX regimen (capecitabine combined with oxaliplatin) on tumor markers, angiogenesis and peripheral blood helper T cell 17 (Th17) / regulatory T cell (Treg) balance in patients with advanced colorectal cancer. Methods: 98 patients with advanced colorectal cancer confirmed by endoscopic biopsy in our hospital from February 2018 to August 2019 were selected as the research objects. According to the random number table method, they were divided into control group ( XELOX regimen chemotherapy, 49 cases) and study group (Aidi injection combined with XELOX chemotherapy regimen, 49 cases). The short-term and long-term efficacy of the two groups were observed, the levels of tumor markers, angiogenesis and Th17 / Treg balance of the two groups were compared before and after treatment, and the drug safety of the two groups was recorded. Results: Compared with the control group, the objective remission rate and disease control rate of the study group were significantly higher (P<0.05). The overall survival rate and progression free survival rate of the study group were higher than those of the control group, but there was no significant difference between the two groups (P>0.05). After treatment, the levels of carcinoembryonic antigen (CEA), sugar chain antigen 125 (CA125) and sugar chain antigen 242 (CA242) of the two groups decreased, and the study group was lower than the control group in the same period (P<0.05). After treatment, the levels of vascular endothelial growth factor (VEGF) and tumor microvessel density (MVD) decreased in the two groups, and the study group was lower than the control group in the same period (P<0.05). After treatment, Th17 ratio and Th17/Treg ratio increased, and Treg ratio decreased in the two groups (P<0.05). After treatment, the Th17 ratio and Th17/Treg ratio of the study group were higher than those of the control group in the same period, and the Treg ratio was lower than that of the control group in the same period (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: Aidi injection combined with XELOX regimen is effective in the treatment of advanced colorectal cancer, which may be related to improving Th17/Treg balance and inhibiting angiogenesis. [ABSTRACT FROM AUTHOR]